ArticleThe open microbiology journal2010
Protection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.
Article in The open microbiology journal, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Postexposure Prophylaxis and Treatment of Bacillus anthracis Infections: A Systematic Review and Meta-analyses of Animal Models, 1947-2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Pooled it
- Antibiotics accumulate inProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Non-vaccinal prophylaxis of tularemia.Frontiers in microbiology · 2024Review
- Tularemia treatment: experimental and clinical data.Frontiers in microbiology · 2023Review
- Antibiotic Therapy of Plague: A Review.Biomolecules · 2021Review
- Genetic Determinants of Antibiotic Resistance inFrontiers in microbiology · 2021Review
- Article
- TheMicrobiology spectrum · 2019Review
- Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia.Scientific reports · 2018Article
- Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics.Antimicrobial agents and chemotherapy · 2018Article
- Evaluation of Combination Drug Therapy for Treatment of Antibiotic-Resistant Inhalation Anthrax in a Murine Model.Antimicrobial agents and chemotherapy · 2017Article
- Identification of New Virulence Factors and Vaccine Candidates forFrontiers in cellular and infection microbiology · 2017Article
- New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.Antimicrobial agents and chemotherapy · 2016Article
- Plague in China 2014-All sporadic case report of pneumonic plague.BMC infectious diseases · 2016Article
- Natural History of Francisella tularensis in Aerosol-Challenged BALB/c Mice.Antimicrobial agents and chemotherapy · 2016Article
- A Rapid Molecular Test for Determining Yersinia pestis Susceptibility to Ciprofloxacin by the Quantification of Differentially Expressed Marker Genes.Frontiers in microbiology · 2016Article
- Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague.Clinical and vaccine immunology : CVI · 2015Article
- A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague.Microbial pathogenesis · 2013Article
- Clinical experimentation with aerosol antibiotics: current and future methods of administration.Drug design, development and therapy · 2013Review
- Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.Clinical and vaccine immunology : CVI · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
Abstract
Successful treatment of inhalation anthrax, pneumonic plague and tularemia can be achieved with fluoroquinolone antibiotics, such as ciprofloxacin and levofloxacin, and initiation of treatment is most effective when administered as soon as possible following exposure. Bacillus anthracis Ames, Yersinia pestis CO92, and Francisella tularensis SCHU S4 have equivalent susceptibility in vitro to ciprofloxacin and levofloxacin (minimal inhibitory concentration is 0.03 μg/ml); however, limited information is available regarding in vivo susceptibility of these infectious agents to the fluoroquinolone antibiotics in small animal models. Mice, guinea pig, and rabbit models have been developed to evaluate the protective efficacy of antibiotic therapy against these life-threatening infections. Our results indicated that doses of ciprofloxacin and levofloxacin required to protect mice against inhalation anthrax were approximately 18-fold higher than the doses of levofloxacin required to protect against pneumonic plague and tularemia. Further, the critical period following aerosol exposure of mice to either B. anthracis spores or Y. pestis was 24 h, while mice challenged with F. tularensis could be effectively protected when treatment was delayed for as long as 72 h postchallenge. In addition, it was apparent that prolonged antibiotic treatment was important in the effective treatment of inhalation anthrax in mice, but short-term treatment of mice with pneumonic plague or tularemia infections were usually successful. These results provide effective antibiotic dosages in mice, guinea pigs, and rabbits and lay the foundation for the development and evaluation of combinational treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.